Efficacy and safety of90Y-DOTATATE therapy in neuroendocrine tumours

Endokrynologia Polska

Volumn 62, Issue 5, 2011, Pages 392-400

  Sowa Staszczak, Anna ^a   Pach, Dorota ^a   Kunikowska, Jolanta ^b   Krolicki, Leszek ^b   Stefanska, Agnieszka ^a   Tomaszuk, Monika ^a   Buziak Bereza, Monika ^a   Mikolajczak, Renata ^c   Matyja, Marta ^a   Gilis Januszewska, Aleksandra ^a   Jabrocka Hybel, Agata ^a   Trofimiuk, Malgorzata ^a   Hubalewska Dydejczyk, Alicja ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c SOLTAN INSTITUTE FOR NUCLEAR STUDIES   (Poland)

Author keywords

Neuroendocrine tumours; Peptide receptor radionuclide therapy; Targeted therapy

Indexed keywords

90 Y TYR3 OCTREOTATE; CHROMOGRANIN A; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OCTREOTIDE[3 TYROSINE]; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STREPTOZOCIN; UNCLASSIFIED DRUG; YTTRIUM 90; 90Y OCTREOTATE, DOTA(0) TYR(3) THR(8); 90Y-OCTREOTATE, DOTA(0)-TYR(3)-THR(8)-; DRUG DERIVATIVE; OCTREOTIDE; ORGANOMETALLIC COMPOUND; YTTRIUM;

ADULT; AGED; ARTICLE; BODY SURFACE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; KIDNEY FUNCTION; LEUKOCYTE; LIVER FUNCTION; MALE; NEUROENDOCRINE TUMOR; PROGRESSION FREE SURVIVAL; RADIOISOTOPE THERAPY; SIDE EFFECT; THROMBOCYTE; GASTROINTESTINAL TUMOR; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; STATISTICS; THYROID TUMOR; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; STATISTICS AS TOPIC; THYROID NEOPLASMS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 83255164664     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005; 46: 62S-66S. (Pubitemid 47619020)
2. 3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998; 75: 406-411.
3. De Jong M, Breeman WA, Bernard BF et al. Receptor-targeted radionuclide therapy using radiolabeled somatostatin analogues tumour size versus curability. Eur J Nucl Med Mol Imaging 2001; 28: 1026P.
4. Behe M, Maecke HR. New somatostatin analogues labelled with technetium-99m. Eur J Nucl Med 1995; 22: 791.
5. 90Y: peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm 2003; 5: 761-768.
6. Bischof Delaloye A. The role of nuclear medicine in the treatment of non-Hodgkin's Lymphoma (NHL). Leuk Lymphoma, 2003; 44: 29-36.
7. Gokhale AS, Mayadev J, Pohlman B, Macklis RM. Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. Int J Radiation Oncology Biol Phys 2005; 63: 194-201. (Pubitemid 41583558)
8. Cremonesi M, Ferrari M, Bodei L et al. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006; 47: 467-1475.
9. 3- octreotate. J Nucl Med 2005; 46: 83S-91S.
10. De Jong M, Valkema R, Jamar F et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32: 133-140. (Pubitemid 34311079)
11. Smith MC, Liu J, Chen T et al. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion 2006; 6: 69-72.
12. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97: 934-959. (Pubitemid 36173145)
13. Plockinger U, Rindi G, Arnold R et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424. (Pubitemid 40874886)
14. 3] octreotide in patients with somatostatin receptor positive tumours. Eur J Nucl Med Mol Imaging 2003; 30 (suppl 2): S232 (abstr).
15. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12: 941-945.
16. Waldherr C, Pless M, Maecke HR et al. Tumor response and clinical benefit in neuroendocrine tumors after 7,4 GBq 90Y-DOTATOC. J Nucl Med 2002; 43: 610-616. (Pubitemid 34507110)
17. 90Y-DOTATOC and nephrotoxicity. Eur J Nucl Med Mol Imaging 2002; 29: 1543.
18. Otte A, Herrmann R, Heppeler A et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26: 1439-1447. (Pubitemid 29515605)
19. Brans B, Bodei L, Giammarile F et al. Clinical radionuclide therapy dosimetry: the quest for the "Holy Grail". Eur J Nucl Med Mol Imaging 2007; 34: 772-786. (Pubitemid 46669368)
20. Rinke A, Muller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with midgut tumors: a report from the PROMID study group. J Clin Oncol 2009; 27: 4656-4663.
21. 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008; 35: 1847-1856.
22. 90Y-DOTATOC in association with amino acid infusion: a phase 1 study. Eur J Nucl Med Mol Imaging 2003; 30: 207-216.
23. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005; 46: 99S-106S.
24. 90Y-DOTA-D- Phe1, Try3-Octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002; 66: 393-398.
25. 3-octreotide. Eur J Nucl Med 2001; 28: 426-434.
26. Chinol M, Bodei L, Cremonesci M, Paganelli G. Receptor-mediated radiotherapy with Y-DOTA-dPHE-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002; 32: 141-147. (Pubitemid 34311080)
27. Valkema R, de Jong M, Bakker WH et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: Rotterdam experience. Semin Nucl Med 2002; 32: 110-122. (Pubitemid 34311077)